Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Project: Research project

Project Details

Description

Narrative Our study will define the immunogenicity of Covid-19 booster vaccinations in patients with a malignant diagnosis. The first study cohort will focus on detectable immunogenicity as defined by standard antibody assays as well as T cell and viral neutralization assays from FDA authorized booster dosing in patients with a cancer diagnosis, while the second study cohort will involve a randomized study to assess the superiority of a “switch” versus conventional booster strategy. These studies will provide pivotal information to best protect our most vulnerable patient populations with a cancer diagnosis.
StatusActive
Effective start/end date12/31/896/30/22

Funding

  • National Cancer Institute: $431,130.00
  • National Cancer Institute: $250,747.00
  • National Cancer Institute: $167,791.00
  • National Cancer Institute: $237,147.00
  • National Cancer Institute: $2,916,911.00
  • National Cancer Institute: $2,916,911.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.